Bilidazum may be available in the countries listed below.
Ingredient matches for Bilidazum
Hyaluronidase is reported as an ingredient of Bilidazum in the following countries:
- Georgia
International Drug Name Search
Bilidazum may be available in the countries listed below.
Hyaluronidase is reported as an ingredient of Bilidazum in the following countries:
International Drug Name Search
Promethazine/Codeine Syrup may cause severe and sometimes fatal breathing problems in children. Do NOT use Promethazine/Codeine Syrup in children younger than 6 years old. Do not give Promethazine/Codeine Syrup with any other medicines that can cause breathing problems.
Treating cough and other upper respiratory symptoms caused by allergies or the common cold. It may also be used for other conditions as determined by your doctor.
Promethazine/Codeine Syrup is a phenothiazine antihistamine and narcotic cough suppressant combination. The antihistamine works by blocking the action of histamine to reduce the symptoms of an allergic reaction, such as runny nose and sinus drainage. The cough suppressant works in the brain to decrease the cough reflex.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Promethazine/Codeine Syrup. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Promethazine/Codeine Syrup. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Promethazine/Codeine Syrup may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Promethazine/Codeine Syrup as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Promethazine/Codeine Syrup.
When used for long periods of time or at high doses, Promethazine/Codeine Syrup may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Promethazine/Codeine Syrup stops working well. Do not take more than prescribed.
Some people who use Promethazine/Codeine Syrup for a long time may develop a need to continue taking it. People who take high doses are also at risk. This is known as DEPENDENCE or addiction. If you stop taking Promethazine/Codeine Syrup suddenly, you may have WITHDRAWAL symptoms. These may include anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; nausea and vomiting; pain; rigid muscles; seeing, hearing, or feeling things that are not there; shivering or tremors; sweating; or trouble sleeping.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Blurred vision; constipation; dizziness; drowsiness; dry mouth, throat, or nose; headache; nausea; tiredness or weakness; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thoughts; agitation; change in the amount of urine produced; confusion; fainting; fast, slow, or irregular heartbeat; hallucinations; loss of coordination; mood or mental changes; muscle pain or stiffness; overexcitement; seizures; severe drowsiness; severe or persistent blurred vision, dizziness, headache, or lightheadedness; slow or irregular breathing; symptoms of infection (eg, fever, chills); tremors; uncontrolled muscle movements (eg, movements of the arms, legs, tongue, eyes); unusual bruising or bleeding; unusual sweating; vision problems; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include cold or clammy skin; coma; dilated or pinpoint pupils; exaggerated reflexes; limp or rigid muscles; loss of consciousness; seizures; severe dizziness; severe drowsiness; slow or difficult breathing; slow or irregular heartbeat.
Store Promethazine/Codeine Syrup at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Promethazine/Codeine Syrup out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Promethazine/Codeine Syrup. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Bacitracin is reported as an ingredient of Baci-IM in the following countries:
International Drug Name Search
Generic Name: metyrosine (me TYE roe seen)
Brand Names: Demser
Metyrosine is used to treat pheochromocytoma (tumor of the adrenal gland).
Metyrosine is given before surgery to control pheochromocytoma, and is also given when surgery is not possible.
Metyrosine may also be used for other purposes not listed in this medication guide.
Call your doctor at once if you have confusion, trouble speaking, tremors, drooling, diarrhea, or painful urination.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely use this medication:
heart disease;
kidney disease; or
liver disease.
Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.
See also: Demser dosage (in more detail)
Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include extreme drowsiness, anxiety, tremors, or tightness of your jaw.
drooling;
difficulty speaking;
tremors;
muscle spasms;
disorientation;
diarrhea; or
painful urination.
Less serious side effects may include:
headache;
drowsiness;
depression, hallucinations, disorientation, and confusion;
stomach upset, vomiting, stomach pain; or
dry mouth.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially medicine to treat psychiatric disorders, such as:
chlorpromazine (Thorazine);
fluphenazine (Permitil, Prolixin);
haloperidol (Haldol);
mesoridazine (Serentil);
perphenazine (Trilafon);
thioridazine (Mellaril); or
trifluoperazine (Stelazine).
This list is not complete and there may be other drugs that can interact with metyrosine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: Demser side effects (in more detail)
Carrashimease may be available in the countries listed below.
Tilactase is reported as an ingredient of Carrashimease in the following countries:
International Drug Name Search
Each EpiPen® Auto-Injector delivers a single dose of 0.3 mg epinephrine injection, USP, 1:1000 (0.3 mL) in a sterile solution.
Each EpiPen® Jr Auto-Injector delivers a single dose of 0.15 mg epinephrine injection, USP, 1:2000 (0.3 mL) in a sterile solution.
The EpiPen® and EpiPen® Jr Auto-Injectors each contain 2 mL epinephrine solution. Approximately 1.7 mL remains in the auto-injector after activation and cannot be used.
Each 0.3 mL in the EpiPen® Auto-Injector contains 0.3 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, and Water for Injection.
The pH range is 2.2-5.0. Each 0.3 mL in the EpiPen® Jr Auto-Injector contains 0.15 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, and Water for Injection. The pH range is 2.2-5.0.
Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is B-(3, 4-dihydroxyphenyl)-a-methyl-aminoethanol, with the following structure:
Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace EpiPen® and EpiPen® Jr Auto-Injectors if the epinephrine solution appears discolored.
EpiPen® and EpiPen® Jr Auto-Injectors do not contain latex.
Epinephrine is the drug of choice for the emergency treatment of severe allergic reactions (Type I) to insect stings or bites, foods, drugs, and other allergens. It can also be used in the treatment of anaphylaxis of unknown cause (idiopathic anaphylaxis) or exercise-induced anaphylaxis. When given intramuscularly or subcutaneously it has a rapid onset and short duration of action. Epinephrine acts on both alpha and beta adrenergic receptors. Through its action on alpha adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation that helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema and may be effective in relieving gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus, and urinary bladder.
EpiPen® and EpiPen® Jr Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EpiPen® and EpiPen® Jr Auto-Injectors are intended for immediate administration in patients, who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (see DOSAGE AND ADMINISTRATION section).
Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema.
EpiPen® and EpiPen® Jr Auto-Injectors are intended for immediate self-administration as emergency supportive therapy only and are not a substitute for immediate medical care.
There are no absolute contraindications to the use of epinephrine in a life-threatening situation.
EpiPen® and EpiPen® Jr Auto-Injectors should only be injected into the anterolateral aspect of the thigh. DO NOT INJECT INTO BUTTOCK. Injection into the buttock may not provide effective treatment of anaphylaxis. Advise the patient to go immediately to the nearest emergency room for further treatment of anaphylaxis.
Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area. Treatment should be directed at vasodilation in addition to further treatment of anaphylaxis (see ADVERSE REACTIONS). Advise the patient to go immediately to the nearest emergency room and to inform the healthcare provider in the emergency room of the location of the accidental injection.
DO NOT INJECT INTRAVENOUSLY. Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine if there is such inadvertent administration.
Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though this product contains sodium metabisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive.
Epinephrine should be administered with caution in patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, e.g., digitalis, diuretics, or anti-arrhythmics, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias. It should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation.
Epinephrine is light sensitive and should be stored in the carrier tube provided. Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) (See USP Controlled Room Temperature). Do not refrigerate. Before using, check to make sure the solution in the auto-injector is not discolored. Replace the auto-injector if the solution is discolored or contains a precipitate.
EpiPen® and EpiPen® Jr Auto-Injectors are not intended as a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.
Epinephrine is essential for the treatment of anaphylaxis. Patients with a history of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs, and other allergens as well as idiopathic and exercise-induced anaphylaxis should be carefully instructed about the circumstances under which epinephrine should be used. It must be clearly determined that the patient is at risk of future anaphylaxis, since the following risks may be associated with epinephrine administration (see DOSAGE and ADMINISTRATION).
Epinephrine should be used with caution in patients who have cardiac arrhythmias, coronary artery or organic heart disease, hypertension, or in patients who are on drugs that may sensitize the heart to arrhythmias, e.g., digitalis, diuretics, quinidine, or other antiarrhythmics. In such patients, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias.
The effects of epinephrine may be potentiated by tricyclic antidepressants and monoamine oxidase inhibitors.
Some patients may be at greater risk of developing adverse reactions after epinephrine administration. These include: hyperthyroid individuals, individuals with cardiovascular disease, hypertension, or diabetes, elderly individuals, pregnant women, pediatric patients under 30 kg (66 lbs.) body weight using EpiPen® Auto-Injector, and pediatric patients under 15 kg (33 lbs.) body weight using EpiPen® J r Auto-Injector.
Despite these concerns, epinephrine is essential for the treatment of anaphylaxis. Therefore, patients with these conditions, and/or any other person who might be in a position to administer EpiPen® or EpiPen® Jr Auto-Injector to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which epinephrine should be used.
Complete patient information, including dosage, direction for proper administration and precautions can be found inside each EpiPen®/EpiPen® Jr Auto-Injector carton.
Epinephrine may produce symptoms and signs that include an increase in heart rate, the sensation of a more forceful heartbeat, palpitations, sweating, nausea and vomiting, difficulty breathing, pallor, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These symptoms and signs usually subside rapidly, especially with rest, quiet and recumbency. Patients with hypertension or hyperthyroidism may develop more severe or persistent effects, and patients with coronary artery disease could experience angina. Patients with diabetes may develop increased blood glucose levels following epinephrine administration. Patients with Parkinson's disease may notice a temporary worsening of symptoms.
In case of accidental injection, the patient should be advised to immediately go to the emergency room for treatment. Since the epinephrine in the EpiPen® Auto-Injector is a strong vasoconstrictor when injected into the digits, hands or feet, treatment should be directed at vasodilation if there is such an inadvertent administration to these areas (see ADVERSE REACTIONS).
Patients who receive epinephrine while concomitantly taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.
The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripe-lennamine and diphenhydramine.
The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol. The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentoloamine. Ergot alkaloids may also reverse the pressor effects of epinephrine.
Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro and to be an oxidative mutagen in a WP2 bacterial reverse mutation assay. Epinephrine had a moderate degree of mutagenicity, and was positive in the DNA Repair test with B. subtilis (REC) assay, but was not mutagenic in the Salmonella bacterial reverse mutation assay.
Studies of epinephrine after repeated exposure in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted. This should not prevent the use of epinephrine under the conditions noted under INDICATIONS AND USAGE.
Pregnancy Category C: There is no study on the acute effect of epinephrine on pregnancy. Epinephrine has been shown to have developmental effects when administered subcutaneously in rabbits at a dose of 1.2 mg/kg daily for two to three days (approximately 30 times the maximum recommended daily subcutaneous or intramuscular dose on a mg/m2 basis), in mice at a subcutaneous dose of 1 mg/kg daily for 10 days (approximately 7 times the maximum daily subcutaneous or intramuscular dose on a mg/m2 basis) and in hamsters at a subcutaneous dose of 0.5 mg/kg daily for 4 days (approximately 5 times the maximum recommended daily subcutaneous or intramuscular dose on a mg/m2 basis). These effects were not seen in mice at a subcutaneous dose of 0.5 mg/kg daily for 10 days (approximately 3 times the maximum recommended daily subcutaneous or intramuscular dose on a mg/m2 basis). Although, there are no adequate and well-controlled studies in pregnant women, epinephrine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse reactions to epinephrine include transient, moderate anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; nausea and vomiting; headache; and/or respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with hypertension or hyperthyroidism. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or certain drugs (see PRECAUTIONS, Drug Interactions). Rapid rises in blood pressure have produced cerebral hemorrhage, particularly in elderly patients with cardiovascular disease. Angina may occur in patients with coronary artery disease. The potential for epinephrine to produce these types of adverse reactions does not contraindicate its use in an acute life-threatening allergic reaction.
Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area (see WARNINGS). Adverse events experienced as a result of accidental injections may include increased heart rate, local reactions including injection site pallor, coldness and hypoaesthesia or injury at the injection site resulting in bruising, bleeding, discoloration, erythema or skeletal injury.
Epinephrine is rapidly inactivated in the body and treatment following overdose with epinephrine is primarily supportive. If necessary, pressor effects may be counteracted by rapidly acting vasodilators or alpha-adrenergic blocking drugs. If prolonged hypotension follows such measure, it may be necessary to administer another pressor drug.
Overdosage of epinephrine may produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients.
Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation. Treatment consists of a rapidly acting alpha-adrenergic blocking drug and/or respiratory support.
Epinephrine overdosage can also cause transient bradycardia followed by tachycardia and these may be accompanied by potentially fatal cardiac arrhythmias. Premature ventricular contractions may appear within one minute after injection and may be followed by multifocal ventricular tachycardia (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by atrial tachycardia and occasionally by atrioventricular block. Treatment of arrhythmias consists of administration of a beta-blocking drug such as propranolol.
Overdosage sometimes results in extreme pallor and coldness of the skin, metabolic acidosis and kidney failure. Suitable corrective measures must be taken in such situations.
EpiPen® or EpiPen® Jr Auto-Injector prescribers should ensure that the patient or caregiver understands the indications and use of this product. A health care provider should review the patient instructions and operation of the EpiPen® or EpiPen® Jr Auto-Injector, in detail, with the patient or caregiver. Inject EpiPen® or EpiPen® Jr intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. See detailed Directions for Use on the accompanying Patient Instructions.
Selection of the appropriate dosage strength is determined according to patient body weight.
EpiPen® Auto-Injector delivers 0.3 mg epinephrine injection (0.3 mL, 1:1000) and is intended for patients who weigh 30 kg or more (approximately 66 pounds or more).
EpiPen® Jr Auto-Injector delivers 0.15 mg epinephrine injection (0.3 mL, 1:2000) and is intended for patients who weigh 15 to 30 kg (33 - 66 pounds).
Each EpiPen® or EpiPen® Jr Auto-Injector contains a single dose of epinephrine. Since the doses of epinephrine delivered from EpiPen® or EpiPen® Jr Auto-Injector are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. The prescriber should carefully assess each patient to determine the most appropriate dose of epinephrine, recognizing the life-threatening nature of the reactions for which this drug is indicated. With severe persistent anaphylaxis, repeat injections with an additional EpiPen® Auto-Injector may be necessary.
Patients should be instructed to periodically visually inspect the epinephrine solution for particulate matter and discoloration. If the solution contains particulate matter or develops a pinkish color or becomes darker than slightly yellow, the patient should immediately contact their physician for a replacement, since these changes indicate that the effectiveness of the drug product may be decreased.
EpiPen® Auto-Injectors (epinephrine injections, USR 1:1000, 0.3 mL) are available in individual cartons, NDC 49502-500-01, and as EpiPen 2-Pak®, NDC 49502-500-02, a pack that contains two EpiPen® Auto-Injectors (epinephrine injections, USP, 1:1000, 0.3 mL) and one EpiPen® Auto-Injector trainer device.
EpiPen® Jr Auto-Injectors (epinephrine injection, USP, 1:2000, 0.3 mL) are available in individual cartons, NDC 49502-501-01, and as EpiPen Jr 2-Pak®, NDC 49502-501-02, a pack that contains two EpiPen® Jr Auto-Injectors (epinephrine injections, USP, 1:2000, 0.3 mL) and one EpiPen® Auto-Injector trainer device.
EpiPen 2-Pak® and EpiPen Jr 2-Pak® also includes a S-clip to clip two cases together.
Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) (See USP Controlled Room Temperature).
Contains no latex. Protect from light.
Rx only.
MANUFACTURED FOR Dey, LP.,
NAPA, CALIFORNIA 94558, U.S.A.
by Meridian Medical Technologies, Inc.,
a subsidiary of King Pharmaceuticals®, Inc.,
Columbia, MD 21046, U.S.A.
EpiPen®, EpiPen® Jr, EpiPen 2-Pak®, and EpiPen Jr 2-Pak® are registered trademarks of Mylan, Inc. licensed exclusively to its wholly-owned affiliate, Dey, LP. of Napa California, USA.
09/08
0001497
03-914-00
EpiPen®
(epinephrine) Auto-Injector 0.3 mg
EpiPen® = one dose of 0.30 mg epinephrine (USP, 1:1000, 0.3 mL)
EpiPen® JR
(epinephrine) Auto-Injector 0.15 mg
EpiPen® Jr = one dose of 0.15 mg epinephrine (USP, 1:2000, 0.3 mL)
Pharmacist - Please Dispense this Leaflet with Product
IMPORTANT INFORMATION
The patient and caregiver should read this information carefully before using EpiPen®or EpiPen® Jr Auto-Injector. Please be prepared! Read the entire insert before an emergency occurs! EpiPen® and EpiPen® Jr Auto-Injectors are disposable, prefilled automatic injection devices for use during allergic emergencies. They contain a single dose of epinephrine which you inject into your outer thigh. EpiPen® and EpiPen® Jr Auto-Injector contain no latex. The EpiPen® and EpiPen®Jr Auto-Injectors are intended for people who have been prescribed this medication by their physician.
It's important that you have this emergency medicine with you at all times. If you need additional units to keep at work, school, etc, please talk to your doctor. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is the most important information I should know about EpiPen® and EpiPen® Jr Auto-Injector?
When you have allergic reaction (anaphylaxis) use the EpiPen® or EpiPen® Jr Auto-Injector right away and immediately go to your doctor or emergency room for more medical treatment.
Since you cannot predict when a life-threatening allergic reaction may occur, carry the EpiPen® or EpiPen® Jr Auto-Injector with you at all times.
What is EpiPen®/EpiPen® Jr Auto-Injector?
The EpiPen® and EpiPen® Jr Auto-Injectors are products used for the emergency injection of epinephrine. Epinephrine is a medicine used for life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure. Allergic reactions can be caused by stinging and biting insects, allergy injections, food, medicines, exercise, or unknown causes.
Life-threatening allergic reactions may show up as closing of your breathing airways, wheezing, sneezing, hoarseness, hives, itching, swelling, skin redness, fast heartbeat, weak pulse, feeling very anxious, confusion, stomach pain, losing control of urine or bowel movements (incontinence), faintness, or "passing out" (unconsciousness).
The EpiPen® Auto-Injector (0.3 mg) is generally intended for patients who weigh 66 pounds or more (30 kilograms or more).
The EpiPen® Jr Auto-Injector (0.15 mg) is generally intended for patients who weigh approximately 33 to 66 pounds (15 to 30 kilograms).
Who should not use EpiPen®/EpiPen® Jr Auto-Injector?
There are no absolute contraindications to the use of EpiPen® and EpiPen® Jr Auto-Injector in a life-threatening allergic reaction. People with certain medical conditions have a higher chance of having serious side effects from EpiPen® or EpiPen® Jr Auto-Injector.
Tell your doctor and pharmacist about all your medical conditions, but especially if you:
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Inform your doctor of all known allergies. Some medicines may cause serious side effects if taken while you use EpiPen®/EpiPen® Jr Auto-Injector. Some medicines may affect how EpiPen®/EpiPen® Jr Auto-Injector works.
EpiPen® or EpiPen" Jr Auto-Injector may affect how your other medicines work.
What should I avoid while using EpiPen®/EpiPen® Jr Auto-Injector?
What are the possible side effects of EpiPen®/ EpiPen® Jr Auto-Injector?
Too much epinephrine can cause dangerous high blood pressure or stroke.
If you take certain medicines, you may develop serious life-threatening side effects from the epinephrine in EpiPen®/ EpiPen® Jr Auto-Injector. Be sure to tell your doctor all the medicines you take, especially medicines for asthma.
Patients with certain medical conditions, or who take certain medicines, may get more side effects from EpiPen®/ EpiPen® Jr Auto-Injector or the side effects may last longer. This includes patients who take certain types of medicines for asthma, allergies, depression, low thyroid, high blood pressure, and heart disease. Patients with heart disease may feel chest pain (angina).
EpiPen®/EpiPen® Jr Auto-Injector (epinephrine) can cause the following reactions. Some reactions can be serious. They usually go away with rest. Please notify your doctor if you experience any of these.
Common side effects of EpiPen®/EpiPen® Jr Auto-Injector include:
These are not all the possible side effects of
EpiPen®/EpiPen® Jr Auto-Injector.
For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
How should I store EpiPen® /EpiPen® Jr Auto-Injector?
SEE OTHER SIDE FOR "DIRECTIONS FOR USE" AND FOR EpiPen® CENTER FOR ANAPHYLACTIC SUPPORT™
FREE ENROLLMENT FORM.
TO REMOVE AUTO-INJECTOR FROM THE CARRIER TUBE:
TO USE AUTO-INJECTOR:
Note: Most of the liquid (about 85%) stays in the auto-injector and cannot be reused. However, you have received the correct dose of the medication if the orange needle tip is extended and the window is obscured. Trainer label has blue background color. Blue background labeled trainer contains no needle and no drug.
! WARNING !
To dispose of expired units
IMMEDIATELY AFTER USE
Do not attempt to take the auto-injector apart.
Manufactured for Dey, L.P., Napa, CA 94558 USA.
by Meridian Medical Technologies™, Inc.
Columbia, MD 21046 USA.
A subsidiary of King Pharmaceuticals® Inc.
EpiPen® is a registered trademark of Mylan, Inc. licensed exclusively to its wholly-owned affiliate, Dey, LP. of Napa California, USA
Design and Utility patents applied for Carrier Tube and Auto-Injector design platform.
©2008 by Meridian Medical Technologies™, Inc.
04/2008
03-855-00
0001496
SEE OTHER SIDE FOR MORE INFORMATION.
NDC 49502-500-01
See other side for instructions
Rx only
After use, most of liquid stays in auto-injector and can't be reused.
Delivers 0.3 mg intramuscular dose of epinephrine from epinephrine injection 1:1000 USP (0.3 mL).
Each 0.3 mL also contains 1.8 mg sodium chloride and 0.5 mg sodium metabisulfite.
EpiPen ® 0.3 mg Epinephrine Auto-Injector for Allergic Emergencies (Anaphylaxis)
REPLACE
IF SOLUTION IS DISCOLORED
STORE AT 25°C (77°F); EXCURSIONS PERMITTED TO 15-30°C (59-86°F)
DO NOT REFRIGERATE. PROTECT FROM LIGHT. CONTAINS NO LATEX.
Dey ® Mfd. For Dey, L.P., Napa, CA 94558 USA by Meridian Medical Technologies ™ , Inc.
Columbia, MD 21046 USA
A subsidiary of King Pharmaceuticals ® , Inc.
EpiPen ® 0.3 mg Epinephrine Auto-Injector
NDC 49502-501-01
See other side for instructions
Rx only
After use, most of liquid stays in auto-injector and can't be reused.
Delivers 0.15 mg intramuscular dose of epinephrine from epinephrine injection 1:2000 USP (0.3 mL).
Each 0.3 mL also contains 1.8 mg sodium chloride and 0.5 mg sodium metabisulfite.
EpiPen ® Jr
0.15 mg Epinephrine Auto-Injector for Allergic Emergencies (Anaphylaxis)
REPLACE
IF SOLUTION IS DISCOLORED
STORE AT 25°C (77°F); EXCURSIONS PERMITTED TO 15-30°C (59-86°F)
DO NOT REFRIGERATE. PROTECT FROM LIGHT. CONTAINS NO LATEX.
Dey ® Mfd. For Dey, L.P., Napa, CA 94558 USA by Meridian Medical Technologies ™ , Inc.
Columbia, MD 21046 USA
A subsidiary of King Pharmaceuticals ® , Inc.
EpiPen® Jr 0.15 mg Epinephrine Auto-Injector
NDC 49502-500-01
Rx only
New Product Appearance!
For Allergic Emergencies (Anaphylaxis) 0.3 mg each
EpiPen ® (Epinephrine) Auto-Injector 0.3 mg
OPEN IMMEDIATELY
EpiPen ® Center for Anaphylactic Support ™
FREE MEMBERSHIP – Details Inside
Dey ®
NDC 49502-501-01
Rx only
New Product Appearance!
For Allergic Emergencies (Anaphylaxis) 0.15 mg each
EpiPen ® Jr (Epinephrine) Auto-Injector 0.15 mg
OPEN IMMEDIATELY
EpiPen ® Center for Anaphylactic Support ™
FREE MEMBERSHIP – Details Inside
Dey ®
NDC 49502-500-02
Rx only.
New Product Appearance!
For Allergic Emergencies (Anaphylaxis) 0.3 mg each
EpiPen 2-Pak ® (Epinephrine) Auto-Injectors 0.3 mg
OPEN IMMEDIATELY
EpiPen ® Center for Anaphylactic Support ™
FREE MEMBERSHIP – Details Inside
Each carton contains 2 EpiPen ® Auto-Injectors and 1 Trainer.
Dey ®
NDC 49502-501-02
Rx only.
New Product Appearance!
For Allergic Emergencies (Anaphylaxis) 0.15 mg each
EpiPen Jr 2-Pak ® (Epinephrine) Auto-Injectors 0.15 mg
OPEN IMMEDIATELY
EpiPen ® Center for Anaphylactic Support ™
FREE MEMBERSHIP – Details Inside
Each carton contains 2 EpiPen ® Jr Auto-Injectors and 1 Trainer.
Dey ®
| EpiPen epinephrine injection | ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA019430 | 12/22/1987 | |
| EpiPen JR epinephrine injection | ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA019430 | 12/22/1987 | |
| Labeler - Dey Pharma L.P. (194775557) |
| Registrant - Meridian Medical Technologies, Inc. (167671341) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Meridian Medical Technologies, Inc. | 038889234 | MANUFACTURE, ANALYSIS, STERILIZE | |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Meridian Medical Technologies, Inc. | 167671341 | MANUFACTURE, LABEL, PACK | |
Broncodil may be available in the countries listed below.
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Broncodil in the following countries:
International Drug Name Search